已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

西妥昔单抗 医学 福克斯 内科学 结直肠癌 肿瘤科 养生 人口 化疗方案 化疗 外科 奥沙利铂 癌症 环境卫生
作者
De‐Shen Wang,Chao Ren,Shanshan Li,William Pat Fong,Xiaojun Wu,Jian Xiao,Binkui Li,Yun Zheng,Peirong Ding,Gong Chen,Miao‐Zhen Qiu,Zhi‐Qiang Wang,Feng‐Hua Wang,Hui Luo,Rui Wang,Xiaozhong Wang,Lingling Wang,De-Jin Xie,Tao Chen,Li Li
出处
期刊:PLOS Medicine [Public Library of Science]
卷期号:21 (5): e1004389-e1004389 被引量:4
标识
DOI:10.1371/journal.pmed.1004389
摘要

Background It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. Methods and findings This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI ( n = 72) or cetuximab plus FOLFOX ( n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus ≥5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann–Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade ≥ 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade ≥ 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. Conclusions The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. Trial Registration ClinicalTrials.gov Identifier: NCT03493048 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
啵啵啵小太阳完成签到,获得积分10
4秒前
FashionBoy应助freshfire采纳,获得10
5秒前
可达鸭完成签到 ,获得积分10
7秒前
聪明静柏完成签到 ,获得积分10
11秒前
Foxjker完成签到 ,获得积分10
12秒前
20秒前
SYLH应助ceeray23采纳,获得20
20秒前
饭ff发布了新的文献求助10
26秒前
28秒前
30秒前
31秒前
CNS发布了新的文献求助10
34秒前
freshfire发布了新的文献求助10
35秒前
遥知马完成签到,获得积分10
36秒前
饭ff完成签到,获得积分20
37秒前
一颗滚石完成签到,获得积分10
37秒前
YiXianCoA完成签到 ,获得积分10
42秒前
可爱的函函应助干净涵梅采纳,获得10
44秒前
科研通AI2S应助科研达人采纳,获得10
44秒前
CNS完成签到,获得积分10
46秒前
Angela完成签到,获得积分10
55秒前
betyby完成签到 ,获得积分10
55秒前
sudor123456完成签到,获得积分10
56秒前
隐形曼青应助饭ff采纳,获得10
56秒前
ddfighting完成签到,获得积分10
57秒前
迷人兰花完成签到,获得积分10
1分钟前
ab完成签到,获得积分10
1分钟前
瘦瘦乌龟完成签到 ,获得积分10
1分钟前
Worenxian完成签到 ,获得积分10
1分钟前
冰西瓜完成签到 ,获得积分0
1分钟前
SYLH应助ceeray23采纳,获得20
1分钟前
Owen应助科研达人采纳,获得10
1分钟前
杨程羽发布了新的文献求助10
1分钟前
孤标傲世完成签到 ,获得积分10
1分钟前
魔幻安南完成签到 ,获得积分10
1分钟前
pp‘s完成签到 ,获得积分10
1分钟前
大学生完成签到 ,获得积分10
1分钟前
杨程羽完成签到 ,获得积分10
1分钟前
仙女完成签到 ,获得积分10
1分钟前
传奇3应助LMX采纳,获得10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532047
关于积分的说明 11256141
捐赠科研通 3270918
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216